One needs to read FULLY the results of TauRx trials before recommending fire sale of that asset.
I've been reading them as fully as I can. The point is that the trials were, by definition, a failure -- they missed their primary endpoints. Post-hoc analysis is sketchy.
They just finished their next Phase 3 enrolment. There seems to be growing buzz about tau-type drugs so I hope Dundee can sell TauRx at a reasonable (not firesale) price in the near future. I certainly don't want them to wait until the results of the trial. AD drug trials have a spectacular failure rate.
Of course I'd be very happy to learn your thoughts on their trials. I'm not an expert and would be interested to hear a different perspective.